Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study: Multiple sclerosis (Houndmills, Basingstoke, England)

D Baroncini, M Zaffaroni, L Moiola, L Lorefice, G Fenu, P Iaffaldano, M Simone, F Fanelli, F Patti, E D'Amico, M Capobianco, A Bertolotto, P Gallo, M Margoni, S Miante, N Milani, MP Amato, I Righini, P Bellantonio, C ScandellariG Costantino, E Scarpini, R Bergamaschi, G Mallucci, G Comi, A Ghezzi, on behalf of the iMED Registry, Gruppo di Studio SM-Società Italiana di Neurologia

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: Few data are available on very long-term follow-up of pediatric multiple sclerosis (MS) patients treated with disease modifying treatments (DMTs). OBJECTIVES: To present a long-term follow-up of a cohort of Pediatric-MS patients starting injectable first-line agents. METHODS: Data regarding treatments, annualized relapse rate (ARR), Expanded Disability Status Scale (EDSS) score, and serious adverse event were collected. Baseline characteristics were tested in multivariate analysis to identify predictors of disease evolution. RESULTS: In total, 97 patients were followed for 12.5 ± 3.3 years. They started therapy at 13.9 ± 2.1 years, 88 with interferons and 9 with copaxone. During the whole follow-up, 82 patients changed therapy, switching to immunosuppressors/second-line treatment in 58% of cases. Compared to pre-treatment phase, the ARR was significantly reduced during the first treatment (from 3.2 ± 2.6 to 0.7 ± 1.5, p 
Original languageEnglish
Pages (from-to)399-407
Number of pages9
JournalMultiple Sclerosis
Volume25
Issue number3
DOIs
Publication statusPublished - 2019

Fingerprint Dive into the research topics of 'Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study: Multiple sclerosis (Houndmills, Basingstoke, England)'. Together they form a unique fingerprint.

Cite this